Case Report

Rhabdomyolysis from Simvastatin Triggered by Infection and Muscle Exertion

Authors: Josef Finsterer, MD, PhD, Georg Zuntner, MD

Abstract

A 42-year-old woman received a 6-month course of simvastatin (20 mg/d) for hypercholesterolemia. Despite an infection with fever, fatigue, myalgias, and lumbar pain, she continued to perform her regular sports activities. Neurologic examination revealed bilateral ptosis and slight upper limb weakness. Serum creatine kinase was 41,000 U/L. Needle electromyography was nonspecifically abnormal. Discontinuation of simvastatin and reduction of the sports activities was followed by a prompt continual lowering of the elevated muscle enzymes to normal values over a 2-week period. The patient’s infection, regular sports activity despite the infection, and a suspected mitochondrial defect were regarded as triggers of rhabdomyolysis.


Key Points


* The myotoxic effect of simvastatin may be enhanced by viral infection.


* The myotoxic effect of simvastatin may be enhanced by sport activity.


* Withdrawal of simvastatin results in immediate, complete recovery from rhabdomyolysis.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Finsterer J. Fibrat-/StatinMyopathie. Nervenarzt 2003;74:115–22.
 
2. Hamilton-Craig I. Statin-associated myopathy. Med J Aust 2001;175:486–489.
 
3. Andreou ER, Ledger S. Potential drug interaction between simvastatin and danazol causing rhabdomyolysis. Can J Clin Pharmacol 2003;10:172–174.
 
4. Matzno S, Tazuya-Murayama K, Tanaka H, et al. Evaluation of the synergistic adverse effects of concomitant therapy with statins and fibrates on rhabdomyolysis. J Pharm Pharmacol 2003;55:795–802.
 
5. Roten L, Schoenenberger RA, Krahenbuhl S, et al. Rhabdomyolysis in association with simvastatin and amiodarone. Ann Pharmacother 2004;38:978–981.
 
6. Riesco-Eizaguirre G, Arpa-Gutierrez FJ, Gutierrez M, et al. Severe polymyositis with simvastatin use.Rev Neurol 2003;37:934–936.
 
7. Goli AK, Goli SA, Byrd RP Jr, et al. Simvastatin-induced lactic acidosis: a rare adverse reaction? Clin Pharmacol Ther 2002;72:461–464.
 
8. Phillips PS, Haas RH, Bannykh S, et al. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 2002;137:581–585.
 
9. Jamil S, Iqbal P. Rhabdomyolysis induced by a single dose of a statin. Heart 2004;90:e3.
 
10. Matsuyama K, Nakagawa K, Nakai A, et al. Evaluation of myopathy risk for HMG-CoA reductase inhibitors by urethane infusion method. Biol Pharm Bull 2002;25:346–350.
 
11. Morales D, Chung N, Zhu JR, et al. Efficacy and safety of simvastatin in Asian and non-Asian coronary heart disease patients: a comparison of the GOALLS and STATT studies. Curr Med Res Opin2004;20:1235–1243.
 
12. de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004;292:1307–1316.
 
13. Skrabal MZ, Stading JA, Monaghan MS. Rhabdomyolysis associated with simvastatin-nefazodone therapy. South Med J 2003;96:1034–1035.
 
14. Aboulafia DM, Johnston R. Simvastatin-induced rhabdomyolysis in an HIV-infected patient with coronary artery disease. AIDS Patient Care STDS 2000;14:13–18.
 
15. Sinzinger H, O’Grady, J. Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems. Br J Clin Pharmacol 2004;57:525–528.
 
16. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239–245.
 
17. Caldwell SH, Hespenheide EE, von Borstel RW. Myositis, microvesicular hepatitis, and progression to cirrhosis from troglitazone added to simvastatin. Dig Dis Sci 2001;46:376–378.